Date published: 2025-12-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

CCT036477 (CAS 305372-78-5)

0.0(0)
Write a reviewAsk a question

See product citations (1)

Alternate Names:
α-(4-Chlorophenyl)-2-methyl-N-2-pyridinyl-1H-indole-3-methanamine
Application:
CCT036477 is an inhibitor of Wnt signaling
CAS Number:
305372-78-5
Purity:
≥98%
Molecular Weight:
347.84
Molecular Formula:
C21H18ClN3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

CCT036477 is a chemical compound recognized for its role as an inhibitor of the Wnt signaling pathway, a critical regulator of cellular communication involved in numerous biological processes, including cell proliferation, migration, and polarity. Specifically, CCT036477 targets the pathway by inhibiting the transcriptional activity mediated by β-catenin, a central player in the Wnt signaling cascade. The mechanism of action of CCT036477 is particularly interesting because it disrupts the interaction between β-catenin and its co-factors in the nucleus, thereby preventing the transcription of Wnt target genes. This inhibition is significant as it allows researchers to study the effects of Wnt signaling suppression in various cellular contexts, without affecting the upstream components of the pathway. In scientific research, CCT036477 has been utilized to explore the role of Wnt signaling in controlling cell fate decisions and in maintaining the balance between stem cell renewal and differentiation. The ability of CCT036477 to selectively inhibit Wnt/β-catenin mediated transcription provides a valuable tool for dissecting the complex network of signals that govern cellular behavior and for understanding how aberrations in this pathway can influence cellular function.


CCT036477 (CAS 305372-78-5) References

  1. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.  |  Ewan, K., et al. 2010. Cancer Res. 70: 5963-73. PMID: 20610623
  2. In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-OΔN89β-catenin system.  |  Jardé, T., et al. 2013. Oncogene. 32: 883-93. PMID: 22469981
  3. Targeting Wnt pathway in mantle cell lymphoma-initiating cells.  |  Mathur, R., et al. 2015. J Hematol Oncol. 8: 63. PMID: 26048374
  4. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.  |  Barghout, SH., et al. Biochem Biophys Res Commun. 468: 173-8. PMID: 26522223
  5. A functional connectome: regulation of Wnt/TCF-dependent transcription by pairs of pathway activators.  |  Freeman, J., et al. 2015. Mol Cancer. 14: 206. PMID: 26643252
  6. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.  |  Taipaleenmäki, H., et al. 2016. Oncotarget. 7: 79032-79046. PMID: 27738322
  7. Trypanosoma cruzi Exploits Wnt Signaling Pathway to Promote Its Intracellular Replication in Macrophages.  |  Volpini, X., et al. 2018. Front Immunol. 9: 859. PMID: 29743880
  8. N-methyl-N-nitrosourea induces zebrafish anomalous angiogenesis through Wnt/β-catenin pathway.  |  Fu, S., et al. 2022. Ecotoxicol Environ Saf. 239: 113674. PMID: 35623148
  9. Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells.  |  Serttas, R. and Erdogan, S. 2023. Med Oncol. 40: 194. PMID: 37264204
  10. Aloe-emodin exhibits growth-suppressive effects on androgen-independent human prostate cancer DU145 cells via inhibiting the Wnt/β-catenin signaling pathway: an in vitro and in silico study.  |  Hussain, T., et al. 2023. Front Pharmacol. 14: 1325184. PMID: 38348349

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

CCT036477, 5 mg

sc-391631A
5 mg
$107.00

CCT036477, 25 mg

sc-391631
25 mg
$428.00